Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia

General Anesthesia Clinical Trial

Official title:

A Multicenter, Randomized, Double-blinded, Propofol-controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HSK3486 Injectable Emulsion for Induction of General Anesthesia in Adults Undergoing Elective Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05478174
• Other study ID #: HSK3486-305
• Status: Completed
• Phase: Phase 3
• Start date: July 26, 2022
• Est. completion date: November 14, 2023

Study information

• Verified date: November 2023
• Source: Haisco-USA Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous [IV] slow injection over 30 [±5] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection over 30 [±5] seconds for first dose, an additional 1.0 mg/kg if needed) in success of induction of general anesthesia in adults undergoing elective surgery.

Description:

This is a multicenter, randomized, double-blinded, propofol-controlled, phase 3 clinical study to evaluate the efficacy and safety of HSK3486 for induction of general anesthesia in adults undergoing elective surgery with endotracheal intubation. After screening, eligible subjects will be randomized in a 2:1 ratio to receive either HSK3486 0.4/0.2 mg/kg (i.e., 0.4 mg/kg IV slow injection over 30 [±5] seconds followed by an additional 0.2 mg/kg dose over 10 [±2] seconds if needed) or propofol 2.0/1.0 mg/kg (i.e., 2.0 mg/kg IV slow injection over 30 [±5] seconds followed by an additional 1.0 mg/kg dose over 10 [±2]seconds if needed) in a blinded manner. Enrolled subjects will be stratified by American Society of Anesthesiologists Physical Status (ASA-PS; I-II and III-IV), age (<65 and ≥65 years), and Body Mass Index (BMI <35 and ≥35 kg/m2). Endotracheal intubation will be performed after adequate anesthetic induction (Modified Observer's Assessment of Awareness/Sedation [MOAA/S] ≤1) (Appendix 1) has been achieved and administration of neuromuscular blocking agent. Before surgery, premedication is allowed except for sedative-hypnotic or analgesic drugs. Premedication should be recorded if used. Prior to administration of the study drug in the operating room, the preoperative readiness of each subject will be confirmed. Oxygen will be supplied through a facemask (oxygen flow rate: ≥4 L/min) at least 2 minutes before study drug administration. Subsequently, the investigator can adjust the oxygen flow according to the specific situation of the subject and maintenance IV solution (normal saline [NS], lactated ringer's [LR], or 5% dextrose) will be administrated through IV infusion. Throughout the preinduction and induction periods, a timing device must be used to allow accuracy and sequencing of necessary assessments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 401
• Est. completion date: November 14, 2023
• Est. primary completion date: November 7, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• 1. Subjects undergoing elective surgery (non emergency, non cardiothoracic, and non intracranial surgery, anticipated to last at least 1 hour) requiring endotracheal intubation and inhalation general anesthesia during the maintenance period. Duration of surgery is defined as time from study drug administration to time of transfer from operating room to recovery room or PACU.

2. Males or females, aged =18 years old, with ASA-PS I to IV (Appendix 6). For ASA-PS IV subjects, clinical status must be optimized at time of preoperative anesthesia evaluation per judgement of the anesthesiologist.

3. BMI =18 kg/m2. 4. Vital signs at screening: RR =10 and =24 breaths/min; SpO2=92% in ambient air; SBP =90 and =160 mmHg; DBP =55 and =100 mmHg; HR =55 (or =50 if subjects are on beta blockers) and =100 beats/min.

5. For all women of childbearing potential, negative serum pregnancy test at screening and must have negative urine pregnancy test at baseline (Day 1). Additionally, women of childbearing potential* must agree to use effective contraception as defined in 7.3.4 from the time of consent until 30 days post study drug administration.

6. Capable of understanding the procedures and methods of this study, willing to sign an Informed Consent Form, and able to complete this study in strict compliance with the study protocol.

7. Willing to comply with the site's COVID guidelines and testing requirements as applicable.

8. Patients with psychiatric/mental disorders must be considered stable on treatment (e.g., SSRIs, SNRIs, TCAs, MAOIs, psychotherapy) and no hospitalizations and urgent care for at least 1 year. *Women NOT of childbearing potential are defined as those who have been surgically sterilized (hysterectomy, bilateral salpingo-oophorectomy) or who are postmenopausal (defined 12 months since last regular menses).

Exclusion criteria:

1. Contraindications to deep sedation/general anesthesia or a history of adverse reaction to sedation/general anesthesia.

2. Known to be allergic to eggs, soy products, opioids and their antidotes, or propofol; subject having contraindications to propofol, opioids, and their antidotes.

3. Medical condition or evidence of increased sedation/general anesthesia risk as

follows:

1. Cardiovascular disorders: uncontrolled hypertension (SBP>160 mmHg and/or DBP >100 mmHg) with or without antihypertensive therapy (antihypertensive therapy should be stable for 1 month prior to screening), serious arrhythmia (including the subjects with implanted pace makers), unstable heart failure, Adams-Stokes syndrome (i.e., syncope or near syncope due to cardiac arrythmia), unstable angina, myocardial infarction occurring within 6 months prior to screening, history of tachycardia/bradycardia requiring medications, third degree atrioventricular block or QT interval corrected for HR using Fridericia's formula (QTcF)=450ms for males and =470ms for females.

2. History of severe obstructive lung disease (i.e., forced expiratory volume in 1 second [FEV1] <50% predicted), history of bronchospasm requiring treatment in a hospital emergency room or hospitalization occurring within 3 months prior to screening, developing acute respiratory tract infection within 2 weeks prior to baseline (such as symptoms of fever, shortness of breath, wheezing, nasal congestion, and cough).

3. Cerebrovascular disease: subject with a history of serious craniocerebral injury, convulsion, seizure disorder, intracranial hypertension, cerebral aneurysm, or stroke.

4. Patients with psychiatric diseases (schizophrenia, mania) who have not been on a stable treatment regimen (with SSRIs, SNRIs, TCAs, MAOIs) for at least 1 year or who have been hospitalized or had emergent/urgent care within the past year.

5. Uncontrolled clinically significant conditions of liver (e.g., severe hepatic insufficiency defined as Childs-Pugh class C), kidney, gastrointestinal tract, blood system, nervous system, or metabolic system diseases, judged by the investigator to be unsuitable for involvement in the study.

6. Known glycosylated hemoglobin (HbA1c) greater than or equal to 10%.

7. Known thyroid-stimulating hormone (TSH) value 10% outside the normal range or on thyroid replacement therapy with a known free T-4 level outside the normal range.

8. History of alcohol abuse within 3 months prior to screening, where alcohol abuse refers to daily alcohol drinking >2 units (1 unit = 360 mL of beer or 45 mL of spirit with a strength of 40% or 150 mL of wine).

9. History of drug abuse that, in the opinion of the investigator, may confound the interpretation of safety or efficacy in a study subject.

4. Management risks of respiratory tract and judged by the investigator to be unsuitable

for inclusion in the study as follows:

1. Asthma must be stable: stable doses of asthma medications for the past 6 months, no requirement for rescue inhalers or oral steroids within past 6 months, not evaluated in emergency department, urgent care, or hospitalized for an asthma attack within past 1 year.

2. History (or family history) of malignant hyperthermia.

3. Any previous failure of tracheal intubation.

4. Judged to have a difficult airway for endotracheal intubation in the opinion of the Investigator based on parameters such as modified Mallampati score (Grade III or IV [Appendix 7], neck mobility, short thyromental distance, and/or history of difficult intubation).

5. Any medication that has the potential to interact synergistically with propofol or HSK3486, including but not limited to all sedatives and hypnotics (e.g., benzodiazepines and opioids) taken within 5 half-lives prior to Day 1.

6. Laboratory parameters measured at screening with the following levels:

1. Neutrophil count =1.5 x 109/L

2. Platelet count <80 x 109/L

3. Hemoglobin <90 g/L (without blood transfusion within 14 days)

4. Alanine transaminase and/or aspartate transaminase =2.0 x upper limit of normal (ULN)

5. Total bilirubin =2.0 x ULN

6. Severe renal impairment defined by creatinine clearance (CrCl) =30 mL/min

7. Female subjects with a positive pregnancy test at screening (serum) or baseline (urine); lactating subjects; any subject planning to get pregnant within 1 month after the study (including the male subject's partner).

8. Judged by the investigator to have any other factors that make the subject unsuitable for participation in the study.

Related Conditions & MeSH terms

• General Anesthesia

Intervention

Drug:
• HSK3486
HSK3486 for induction of general anesthesia
• Propofol
Propofol for induction of general anesthesia.

Locations

Country	Name	City	State
United States	HD Research	Bellaire	Texas
United States	Brigham & Women'S Hospital	Boston	Massachusetts
United States	Hd Research Llc.	Carrollton	Texas
United States	Rush University Medical Center	Chicago	Illinois
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	The Ohio State University Wexner Medical Center	Columbus	Ohio
United States	UC Davis Health	Davis	California
United States	Midwest Clinical Research Center	Dayton	Ohio
United States	Duke University Health	Durham	North Carolina
United States	The University of Texas - MD Anderson Cancer Center	Houston	Texas
United States	Coastal Clinical Research Specialists	Jacksonville	Florida
United States	University of Miami Hospital	Miami	Florida
United States	Chesapeake Research Group, Llc	Pasadena	Maryland
United States	Arizona Research Center	Phoenix	Arizona
United States	Oregon Health & Science University	Portland	Oregon
United States	Jbr Clinical Research	Salt Lake City	Utah
United States	Endeavor Clinical Trials	San Antonio	Texas
United States	Urology San Antonio Research	San Antonio	Texas
United States	Gulfcoast Research Institute, Llc	Sarasota	Florida
United States	Shoals Medical Trials, Inc.	Sheffield	Alabama
United States	Phoenix Clinical Research	Tamarac	Florida
United States	ForCare Clinical Research	Tampa	Florida
United States	NextStage Clinical Research - Abay Neuroscience Center	Wichita	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Haisco-USA Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Success rate of general anesthesia induction	Induction success (MOAA/S =1) after administration of the study drug, and; One or less top-up doses required without using any rescue drugs.	From the time of study drug administration to desired depth of anesthesia to MOAA/S=1 ( up to 5 minutes)
Secondary	Proportion of subjects with successful induction who maintain the desired depth of anesthesia for general elective surgery, AND without significant cardiac and respiratory depression		15 minutes from end of drug administration
Secondary	Proportion of subjects with any injection-site pain on Numeric Rating Scale		From start of drug administration to MOAA/S =1 (up to 3 minutes)